Page top

Japanese Life Science Startups Business Luncheon in London

Welcome to the UNIKORN Business Luncheon in London! Join us for an afternoon of networking and insightful discussions at the prestigious 116 Pall Mall - Institute of Directors.

Japanese life science startups will visit London to explore business partnering opportunities as they consider entering the UK market. Their goals include company formation, clinical trials, business partnerships, and securing investments. Please join us for a business lunch meeting!!

* This event is invitation only.

12 Nov

LONDON

Speaker

The Delegates

FEATURED INDUSTRY EXPERTS

AUXILART

AI drug discovery

Auxilart, a Japanese startup founded in July 2023, is transforming pharmaceutical process development with advanced simulation solutions. By leveraging an innovative approach that requires less than 1% of the data typically needed by conventional AI methods, Auxilart significantly reduces experimental costs and accelerates development timelines, replacing much of the trial-and-error experiments with digital simulations. To date, Auxilart has secured contracts with leading pharmaceutical companies both domestically and globally. A recent project with a major Japanese company demonstrated its impact, saving over $1.5 million and cutting project timelines by six months.

iXgene

Name

iXgene is a Japanese biotech company specializing in gene therapy and regenerative medicine. It focuses on developing advanced cell and gene-based therapies to treat a range of diseases, particularly in the areas of oncology and rare genetic disorders. iXgene leverages cutting-edge technologies, such as induced pluripotent stem cells (iPSCs) and gene-editing tools, to create innovative treatment options.

With a strong emphasis on research and collaboration, the company works closely with academic institutions and pharmaceutical partners to accelerate the development and commercialization of its therapies, aiming to improve patient outcomes and address unmet medical needs.

Regenerative medicine

PeptiGrowth

Regenerative medicine

Name

PeptiGrowth is a Japanese biotech company specializing in the development of innovative, synthetic peptide growth factors. These growth factors are chemically synthesized and do not rely on animal-derived components, making them safer, more consistent, and ethically aligned with modern biomanufacturing needs. PeptiGrowth’s technology addresses challenges in cell culture and regenerative medicine by offering high-quality, customizable peptide-based alternatives that enhance the performance of various biological processes, such as cell proliferation and differentiation. The company’s solutions cater to a broad range of industries, including pharmaceuticals, cosmetics, and life sciences, supporting cutting-edge research and development across the globe.

Agenda

12 November 2024